All In Biotech

Drug Trial Radar · NCT06921928

Study for AZD4360 in Participants With Advanced Solid Tumours

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

31

Actual

Start

Apr 29, 2025

Primary completion

Mar 31, 2027

Study completion Dec 16, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.

Conditions

  • Gastric Cancer
  • Gastroesophageal Junction Cancer
  • Biliary Tract Cancer
  • Pancreatic Ductal Adenocarcinoma

Interventions

  • AZD4360Drug

    Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360Time frame: Through study completion, up to approximately 2 years

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    Santa Monica, California

  • Research Site

    Providence, Rhode Island

  • Research Site

    Houston, Texas

  • Research Site

    Beijing, China

  • Research Site

    Chengdu, China

  • Research Site

    Shanghai, China

  • Research Site

    Wuhan, China

  • Research Site

    Dresden, Germany

  • Research Site

    Frankfurt, Germany

  • Research Site

    Chūōku, Japan

  • Research Site

    Kashiwa, Japan

  • Research Site

    Kōtoku, Japan

  • Research Site

    Glasgow, United Kingdom

  • Research Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.